Collateral Blood Flow: The Body’s Natural Bypass System

When an artery narrows or becomes blocked, the body can reroute blood through small, pre-existing vessels that enlarge and remodel themselves into functional detour routes. These collateral blood vessels act as a built-in backup system, and in some people they grow robust enough to preserve blood flow to the heart, brain, or limbs even when a major artery is severely obstructed. The process is not instantaneous or guaranteed, though, and the degree to which any individual develops collateral flow varies enormously based on genetics, physical activity, and underlying health conditions.

How Collateral Vessels Form

The growth of collateral arteries is fundamentally different from what most people picture when they hear “the body grows new blood vessels.” There are actually two distinct processes at work in the vascular system. One, called angiogenesis, involves the sprouting of tiny new capillaries from existing ones. These capillaries are small, fragile, and lack the muscular wall needed to carry meaningful volumes of blood. They form in response to low oxygen levels in tissue and can help with local needs, but they cannot replace a blocked artery’s throughput.

The other process, called arteriogenesis, is what actually builds the body’s bypass system. Rather than growing vessels from scratch, arteriogenesis enlarges and remodels tiny arterial connections that were already present since embryonic development. These pre-existing arteriole-to-arteriole bridges, often barely used under normal conditions, widen and develop muscular walls, eventually becoming fully functional arteries capable of carrying substantial blood flow.

¹ This distinction matters because it explains why collateral growth does not depend on tissue being starved of oxygen. It depends on something else entirely: physical force.

Shear Stress as the Trigger

When a major artery becomes partially or fully blocked, blood that would have flowed through it gets redirected into those small pre-existing bypass routes. The sudden increase in flow through these narrow channels creates friction against the vessel walls, a force known as fluid shear stress. This mechanical stimulus is the primary driver of collateral artery growth. Animal studies have shown that experimentally increasing shear stress in collateral vessels produces a remarkably strong growth response, expanding the number and size of collateral arteries far beyond what occurs naturally.

²

The cellular chain of events that follows is increasingly well understood. When endothelial cells lining the vessel wall sense increased shear stress, they release signaling molecules that trigger smooth muscle cells in the vessel wall to begin remodeling. One pathway involves the release of TGF-β from endothelial cells, which boosts levels of specific microRNAs in smooth muscle cells. These microRNAs help reorganize the structural scaffolding around the vessel, loosening the extracellular matrix so the artery can expand outward.

³

White blood cells called monocytes also play a crucial role. They are recruited to the walls of developing collateral arteries, where they infiltrate the tissue and release growth factors and enzymes that help digest and rebuild the vessel wall. Research in animal models has shown that the concentration of circulating monocytes directly affects how well collateral arteries grow. When monocyte counts were experimentally boosted, collateral development increased and more visible collateral arteries appeared within days.

⁴

What Collateral Flow Means for the Heart

The heart is where collateral circulation has been studied most extensively, and the findings are striking. In patients with coronary artery disease, a well-developed collateral network acts as a genuine lifeline. During a heart attack, collateral vessels can deliver enough blood to the heart muscle to limit the size of the damage, preserve pumping function, and reduce scarring. Over the long term, these benefits translate into better survival.

A ten-year follow-up study of patients with stable coronary artery disease found that those with strong collateral flow during a brief coronary occlusion had their long-term cardiac mortality reduced to roughly one quarter of what it was in patients without meaningful collateral supply.

⁵ An earlier study tracking patients with total coronary artery occlusion found that those with good collaterals had higher ten-year survival rates and were less likely to develop heart failure or suffer a full-blown heart attack. Good collaterals were associated with a lower incidence of abnormal ECG findings and better heart function on imaging.

⁶

These findings make intuitive sense: if enough blood can sneak around a blockage, the downstream tissue never fully starves. But the degree of benefit varies widely between patients, and not everyone with coronary artery disease develops a good collateral network. Understanding why is one of the central puzzles in this field.

Collaterals in the Brain

The brain has its own collateral systems, the most well-known being the circle of Willis, a ring of arteries at the base of the brain that connects the major arterial supplies. In theory, if one feeding artery becomes blocked, blood can flow through the ring to reach the affected side. In practice, the circle of Willis is anatomically complete in only a fraction of people. Many individuals have one or more segments that are too small or absent altogether, which limits the ring’s ability to compensate for a blockage.

⁷ Studies using ultrasound and autopsy comparisons have confirmed that the functional versus non-functional segments differ substantially in diameter, with functional collateral segments measuring roughly twice the diameter of non-functional ones.

⁸

Beyond the circle of Willis, the brain also has leptomeningeal (pial) anastomoses, fine connections between branches of different cerebral arteries along the brain’s surface. These come into play during ischemic stroke, and their quality has a dramatic effect on outcomes. A meta-analysis found that stroke patients with good collateral blood flow had roughly double the odds of a favorable clinical outcome at 90 days compared to those with poor collateral flow, regardless of whether they received clot-busting drugs or underwent clot-retrieval procedures. Good collateral status was also associated with substantially lower risks of brain hemorrhage and death.

⁹

Certain anatomical variants of the posterior circle of Willis are particularly dangerous. Computational modeling has shown that a configuration called the “full fetal type,” where the posterior cerebral arteries are fed entirely by the internal carotid arteries rather than the vertebral system, leaves the brain especially vulnerable if one of those carotid arteries becomes blocked.

¹⁰

Collaterals in the Legs and Gut

Peripheral artery disease, which most commonly affects the legs, is another area where collateral vessels make a measurable difference. When plaque builds up in the arteries supplying the legs, collateral pathways can partially compensate. Research using MRI-based imaging found that among people with peripheral artery disease, those with fewer and smaller collateral vessels combined with heavy plaque buildup experienced the fastest decline in walking speed over time. In contrast, patients with more numerous collateral vessels maintained their mobility better, even when their underlying disease was severe.

¹¹

Interestingly, having more and larger collateral vessels in the legs is itself a marker of more advanced disease. People with the most developed collateral networks also tend to have the most plaque and the lowest ankle blood pressure readings, which makes sense: the body builds the bypass because the main road is badly blocked.

¹² The collaterals are a response to the problem, not a sign that the problem is absent.

The gut has its own collateral network as well. The marginal artery of Drummond runs along the length of the colon, connecting branches of the major mesenteric arteries. When one of those arteries narrows, this collateral pathway can protect the bowel from ischemic injury. Surgeons rely on this anatomy during operations that involve cutting or rerouting intestinal blood supply.

¹³

Exercise and Collateral Growth

If shear stress drives collateral artery development, then exercise, which increases blood flow through the coronary arteries, should logically stimulate the process. And it does. The EXCITE trial tested this in patients with stable coronary artery disease, putting participants through either moderate- or high-intensity exercise for about ten hours per week over four weeks. Collateral flow index, a direct measurement of how much blood reaches tissue through collateral channels, increased by roughly 40% in both exercise groups, while a sedentary control group saw no change at all.

¹⁴

The mechanism aligns with what we know about arteriogenesis: exercise raises heart rate and coronary blood flow, which increases shear stress in pre-existing collateral pathways and triggers the remodeling cascade.

¹⁵ The exercise volume in the EXCITE trial was substantial, though, and the research on minimum effective doses is still thin. Whether casual recreational activity drives meaningful collateral growth remains an open question, but the direction of the evidence is clear: more sustained cardiovascular exercise translates into better collateral development in people who already have coronary disease.

Why Some People Build Better Collaterals Than Others

One of the most puzzling aspects of collateral circulation is the enormous variation between individuals. Two patients with the same degree of coronary blockage may have wildly different collateral networks, and genetics appears to explain a large part of this. Studies in mice have identified multiple regions of the genome that influence both the number and diameter of collateral vessels. One region on chromosome 7 had an outsized effect, accounting for roughly a third of the variation in both collateral number and collateral diameter in one study.

¹⁶

Subsequent work has drilled deeper, identifying specific candidate genes. VEGF-A, a well-known vascular growth factor, influences collateral formation during embryonic development: mice engineered to overexpress VEGF-A formed more collateral vessels, while those with reduced expression formed fewer.

¹⁷ More recent research has identified additional genes such as Rabep2 and Rgs1 that can independently alter collateral abundance when their expression is boosted in low-collateral mouse strains.

¹⁸

The practical implication is that some people are born with a denser pre-existing network of tiny arterial bridges, giving them a head start if they ever develop arterial disease. Others start with fewer and smaller connections, leaving their tissues more vulnerable to ischemia. This inborn variation is something no amount of exercise or medication can fully overcome, though lifestyle factors clearly modify the end result.

Diabetes, Medications, and Other Impairments

Not all modifiable factors work in favor of collateral growth. Diabetes is one of the strongest negative predictors of collateral vessel formation. Research has shown that monocytes from people with diabetes have a severely impaired ability to migrate toward vascular growth signals, a defect traced to broken signaling pathways within the monocytes themselves.

¹⁹ Since monocyte recruitment to the vessel wall is essential for remodeling, this defect hamstrings the entire arteriogenesis process in diabetic patients. The result: people who need collateral flow the most, given their elevated cardiovascular risk, are often the least able to develop it naturally.

Certain common cardiac medications also have unexpected effects. A study measuring coronary collateral flow before and after intravenous metoprolol, a widely used beta-blocker, found that the drug reduced collateral flow in 23 out of 25 patients. Collateral flow index dropped significantly, likely because metoprolol lowered heart rate and reduced the pressure gradient driving flow through collateral channels.

²⁰ This does not necessarily mean beta-blockers are harmful on balance, since they provide other cardiac benefits, but it is a complication that rarely comes up in routine patient discussions.

Therapeutic Attempts and Their Challenges

Given the survival benefits of a good collateral network, researchers have spent decades trying to stimulate collateral growth pharmacologically. Early experiments in the 1990s showed that growth factors like VEGF and bFGF could boost collateral flow in animals, sparking enormous excitement about “therapeutic angiogenesis.” Clinical trials followed, using growth factor proteins injected into the heart muscle and eventually gene therapy approaches designed to sustain growth factor delivery for longer periods.

The results were largely disappointing. Phase II trials of single-agent growth factor therapies showed no treatment effect on primary endpoints.

²¹ The biology turned out to be far more complex than a single growth factor could address. There were also concerns about potential side effects of potent angiogenic molecules, including the theoretical risk of accelerating tumor growth or destabilizing atherosclerotic plaques. This failure prompted a shift in research strategy, moving away from single-compound approaches and toward more nuanced interventions.

²²

One mechanical approach that has shown promise is enhanced external counterpulsation (EECP), a treatment where inflatable cuffs wrapped around the legs squeeze rhythmically in sync with the heartbeat, pushing blood back toward the heart during the resting phase of each cycle. A randomized controlled trial found that EECP significantly increased coronary collateral flow index compared to a sham treatment.

²³ The logic fits the shear stress model: by artificially boosting blood flow through collateral channels, EECP recreates the mechanical stimulus that drives arteriogenesis without requiring the patient to exercise vigorously.

More recently, researchers have explored stem cell-based strategies. Studies in rats have demonstrated that bone marrow-derived stem cells, when stimulated by repeated brief episodes of ischemia, can home to the heart, differentiate into endothelial cells, and incorporate into the walls of growing collateral vessels. When a specific population of these stem cells (CD34+ cells) was depleted, collateral growth was impaired, confirming their functional importance.

²⁴ These findings remain preclinical, but they point toward a different therapeutic philosophy: instead of flooding the area with a single growth factor, support the cellular machinery the body already uses for collateral development.

Seeing Collateral Flow Without Surgery

Historically, the only way to visualize collateral vessels was through invasive catheter-based angiography. That is changing. Multiple non-invasive imaging techniques now allow doctors to assess collateral circulation without threading a catheter into the patient’s arteries.

In the brain, transcranial color-coded duplex ultrasonography can detect the presence and direction of collateral flow through the circle of Willis, and the results correlate well with what autopsy findings show.

⁸ A more advanced ultrasound technique called color velocity imaging quantification can not only detect intracranial collateral flow but also measure its magnitude, making it useful for monitoring patients with severe carotid artery narrowing over time.

²⁵

MRI-based methods have also advanced substantially. Selective magnetic resonance angiography can suppress the signal from one artery at a time, allowing clinicians to see exactly which collateral pathways are carrying blood and where it is going. In patients with cervical carotid stenosis, this technique has matched the findings of traditional catheter angiography while being entirely non-invasive.

²⁶ Dynamic MRI angiography using arterial spin labeling goes a step further by tracking labeled blood as it flows through the circle of Willis in real time, generating movies of collateral flow patterns and calculating arrival times at different locations.

²⁷

These imaging advances matter for clinical decision-making. In stroke, knowing whether a patient has good or poor collateral flow can influence whether aggressive clot-retrieval procedures are attempted and how quickly they need to happen. In coronary and peripheral artery disease, quantifying collateral flow helps cardiologists and vascular surgeons gauge how much protection a patient already has before deciding on revascularization procedures.

The Paradox of a Backup System You Cannot Count On

Collateral blood flow occupies an unusual space in medicine. It is clearly protective, sometimes dramatically so. Yet it cannot be reliably prescribed, engineered, or even predicted in a given patient. Genetic lottery determines the starting hardware. Chronic disease processes like diabetes undermine the remodeling machinery. Exercise helps, but requires a volume and intensity that not all patients with arterial disease can achieve. Pharmacological shortcuts have so far failed to deliver in clinical trials, and the most promising stem cell approaches remain experimental.

What has improved is the ability to see and measure collateral flow, which is reshaping how clinicians think about risk stratification. Two patients with the same angiographic blockage may face very different prognoses, and collateral status helps explain why. Increasingly, imaging of collateral pathways is factored into treatment planning for both stroke and coronary artery disease, turning what was once an incidental finding on angiography into an actionable piece of clinical information.